MallucheH.H., LangubM.C., Monier–FaugereM.C.The role of bone biopsy in clinical practice and research.Kidney Int Suppl1999; 73: S20–5.
2.
Monier–FaugereM.C., MallucheH.H.Trends in renal osteodystrophy: A survey from 1983 to 1995 in a total of 2248 patients.Nephrol Dial Transplant1996; 11: 111–20.
3.
SherrardD.J., HerczG., PeiY., MaloneyN.A., GreenwoodC., ManuelA.The spectrum of bone disease in end-stage renal failure — an evolving disorder.Kidney Int1993; 43: 436–42.
4.
AdamsJ.E.Renal bone disease: Radiological investigation.Kidney Int Suppl1999; 73: S38–41.
SilverJ., YalcindagC., Sela–BrownA., KilavR., Naveh–ManyT.Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate.Kidney Int Suppl1999; 73: S2–7.
7.
CouttenyeM.M., D'HaeseP.C., VerschorenW.J., BehetsG.J., SchrootenI., De BroeM.E.Low bone turnover in patients with renal failure.Kidney Int Suppl1999; 73: S70–6.
8.
SherrardD., BaylinkD., WergedalJ.Bone disease in uremia.Trans Am Soc Artif Intern Organs1972; 28: 412–15.
9.
LlachF., FelsenfeldA.J., ColemanM.D., KeveneyJ.J., PedersonJ.A., MedlockT.R.The natural course of dialysis osteomalacia.Kidney Int Suppl1986; 18: S74–9.
10.
MorinièreP., Cohen–SolalM., BelbrikS., BoudailliezB., BarieA., WesteelP.F.Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting Al(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum.Nephron1989; 53: 93–101.
Cohen–SolalM.E., SebertJ.L., BoudailliezB., WesteelP.F., MorinièreP.H., MarieA.Non-aluminic adynamic bone disease in non-dialyzed uremic patients: A new type of osteopathy due to overtreatment?Bone1992; 13: 1–5.
13.
MallucheH.H., Monier–FaugèreM-CRisk of adynamic bone disease in dialyzed patients.Kidney Int Suppl1992; 38: S62–7.
14.
HutchisonA.J., WhitehouseR.W., BoultonH.F., AdamsJ.E., MawerE.B., FreemontT.J.Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease.Kidney Int1993; 44: 1071–7.
15.
HernandezD., ConcepcionM.T., LorenzoV., MartinezM.E., RodriguezA., De BonisE.Adynamic bone disease with negative aluminium staining in predialysis patients: Prevalence and evolution after maintenance dialysis.Nephrol Dial Transplant1994; 9: 517–23.
16.
TorresA., LorenzoV., HernandezD., RodriguezJ.C., ConcepcionM.T., RodriguezA.P.Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH.Kidney Int1995; 47: 1434–42.
17.
HamdyN.A.T., KanisJ.A., BenetonM.N.C., BrownC.B., JuttmanJ.R., JordansJ.G.M., JosseS., MeyrierA., LinsR.L., FaireyI.T.Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.Br Med J1995; 310: 358–63.
18.
CoenG., MazzaferroS., BallantiP., SardellaD., ChiccaS., ManniM.Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study.Nephrol Dial Transplant1996; 11: 813–19.
19.
CoburnJ.W.Mineral metabolism and renal bone disease: Effects of CAPD versus hemodialysis.Kidney Int Suppl1993; 40: S92–100.
20.
HerczG., SherrardD.J., ChanW., PeiY.Aplastic osteo-dystrophy: Follow-up after 5 years (Abstract).J Am Soc Nephrol1994; 5: 851.
21.
TurnerM.W., ArdilaM., HutchinsonT., PrichardS., BarreP.E., BeauvaisJ.Sporadic aluminum osteomalacia: Identification of patients at risk.Am J Kidney Dis1988; 21: 51–6.
22.
IhleB., BeckerG., Kincaid–SmithP.Clinical and biochemical features of aluminum-related bone disease.Kidney Int Suppl1986; 18: S80–6.
23.
NorrisK., GoodmanW., HowardN., NugentM., CoburnJ.Iliac crest bone biopsy for diagnosis of aluminum toxicity and a guide to the use of deferoxamine.Semin Nephrol1986; 6(4 Suppl 1): S27–34.
24.
HerczG., AndressD., NebekerH., ShinabergerJ., SherrardD., CoburnJ.Reversal of aluminum-related bone disease after substituting calcium carbonate for aluminum hydroxide.Am J Kidney Dis1988; 11: 70–5.
25.
MallucheH., SmithA., AbreoK., FaugèreM-CThe use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure.N Engl J Med1984; 311: 140–4.
26.
PeiY., HerczG., SherrardD., SegreG., ManuelA., SaiphooC.Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients.Kidney Int1992; 41: 1374–82.
27.
MillinerD., NebekerH., OttS., AndressD., SherrardD., AlfreyA.Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy.Ann Intern Med1984; 101: 775–80.
28.
D'HaeseP., CouttenyeM., GoodmanW., LemoniatouE., DigenisP., SotornikI.Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity or aluminium overload.Nephrol Dial Transplant1995; 10: 1874–84.
29.
WinneyR., CowieJ., RobsonJ.Role of plasma aluminum in the detection and prevention of aluminum toxicity.Kidney Int Suppl1986; 18: S91–5.
30.
D'HaeseP., ClementJ., ElseviersM., LambertsL., Van de VyverF., VisserW.Value of serum aluminium monitoring in dialysis patients: A multicentre study.Nephrol Dial Transplant1990; 5: 45–53.
31.
CharhonS., ChavassieuxP., MeunierP., AccominottM.Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis.Br Med J1985; 290: 1613–14.
32.
NebekerH., AndressD., MillinerD., OttS., AlfreyA., SherrardD.Indirect methods for the diagnosis of aluminum bone disease. Plasma aluminum, the desferrioxamine infusion test, and serum iPTH.Kidney Int Suppl1986; 18: S96–9.
33.
KauszA.T., AntonsenJ.E., GerczG., PeiY., WeissN.S., EmersonS.Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients.Am J Kidney Dis1999; 34: 688–93.
34.
HerczG., SaluskyI.B., NorrisK.C., CoburnJ.W.Aluminum removal by peritoneal dialysis: Effect of intraperitoneal versus intravenous desferrioxamine.Kidney Int1986; 30: 944–8.
35.
SwartzR.Deferoxamine and aluminum removal.Am J Kidney Dis1985; 6: 358–64.
